title: Safe intravenous antibiotic therapy at home: experience of a UK based programme.
abstract: Outpatient i.v. antibiotic therapy is well developed in the United States, largely because of pressures from third-party payers to reduce costs of medical care. We have developed an outpatient i.v. antibiotic programme in Oxford, that has evolved from a desire to provide high quality i.v. therapy to AIDS patients with cytomegalovirus retinitis. We describe the rationale of the service and report on our first two years' experience. We treated 67 consecutive patients (eight with HIV infection) at home with i.v. antibiotics. This resulted in a saving of 2275 hospital days for those patients without HIV infection. HIV positive patients received 69 months of home i.v. therapy. Minor intravascular catheter complications occurred in only five patients (7.5%). The only serious complications were three episodes of catheter-related sepsis (4.5%), all occurring in AIDS patients who had lines in for more than six months. We have shown that home i.v. antibiotic therapy can be delivered safely to patients with a wide variety of infectious problems using the existing network of community nurses in the National Health Service. Essential components to the programme include a multidisciplinary team working between the hospital and community and a written shared care protocol. Such a programme can result in reduced lengths of hospital stay and patient, community nurse and physician satisfaction.
authors: East Oxford Health Centre, UK.
authors: J
authors: J
authors: Kayley
authors: A R
authors: AR
authors: Berendt
authors: M J
authors: MJ
authors: Snelling
authors: H
authors: H
authors: Moore
authors: H C
authors: HC
authors: Hamilton
authors: T E
authors: TE
authors: Peto
authors: D W
authors: DW
authors: Crook
authors: C P
authors: CP
authors: Conlon
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology; D002443:Ceftriaxone / Q000008:administration & dosage / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006699:Home Care Services / Q000458:organization & administration; D018718:Home Infusion Therapy / Q000191:economics* / Q000451:nursing / Q000706:statistics & numerical data*; D006801:Humans; D017063:Outcome Assessment, Health Care; D006113:United Kingdom; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D005839:Gentamicins; D014640:Vancomycin; D002443:Ceftriaxone; D015774:Ganciclovir